Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520738 | 1.00 | FUCA1 (0.31) | FUCA1 | |
| SCHEMBL5575978 | 0.85 | FUCA1 (0.32) | FUCA1 | |
| SCHEMBL5575973 | 0.85 | FUCA1 (0.32) | FUCA1 | |
| SCHEMBL6515149 | 0.81 | DNM1 (0.35) | FUCA1 | |
| SCHEMBL6515145 | 0.81 | DNM1 (0.35) | FUCA1 | |
| SCHEMBL6517209 | 0.80 | NPC1 (0.33) | FUCA1 | |
| SCHEMBL6517205 | 0.80 | NPC1 (0.33) | FUCA1 | |
| SCHEMBL5575339 | 0.78 | FUCA1 (0.33) | FUCA1 | |
| SCHEMBL5575333 | 0.78 | FUCA1 (0.33) | FUCA1 | |
| Hydrogen Sulfide SCHEMBL4468953 | 0.77 | PYGB (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272670-A1 | Synthesis and use of glycodendrimer reagents | DAVIS BENJAMIN G | 2005-12-08 | — | — | US | disclosed |
| US-6627744-B2 | A chemically modified mutant protein, e.g. an enzyme, having a substituted cysteine reacted with a glyosyslated thiosulfate; high esterase activity and low amidase activity of subtilisins; protease to degrade lectins | GENENCOR INTERNATIONAL, INC. | 2003-09-30 | — | — | US | disclosed |
| US-20020019039-A1 | Synthesis and use of glycodendrimer reagents | GENENCOR INTERNATIONAL, INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019039-A1 | Synthesis and use of glycodendrimer reagents | STT3A, STT3B, PTMS | FUCA1 408/4885 |
| US-20050272670-A1 | Synthesis and use of glycodendrimer reagents | STT3A, PTMS, STT3B | FUCA1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.